Modality
ERT
MOA
CAR-T CD19
Target
Cl18.2
Pathway
Hedgehog
T2DRCCBladder Ca
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Apr 2027
Phase 1Current
NCT05099731
238 pts·Bladder Ca
2019-02→2027-04·Active
238 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-041.0y awayInterim· Bladder Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Active
Catalysts
Interim
2027-04-04 · 1.0y away
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05099731 | Phase 1 | Bladder Ca | Active | 238 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP |